Search Results
Your search for ASCO,ASCO matches 21602 pages
Showing 1 - 50
Nicholas J. Short, MD: Focus on TP53-Mutated ALL
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses TP53 abnormalities in acute lymphoblastic leukemia (ALL), which are uncommon in pediatric patients but may occur in 10% to 15% of adult patients with ALL. Dr. Short reviews recent research into their impact on...
Study Finds Postapproval Cancer Trials Fell After Inflation Reduction Act
Research published by Zheng et al in Health Affairs Scholar found that the passage of the government price-setting provisions of the Inflation Reduction Act (IRA) was associated with a broad decline in industry-funded oncology trials after first U.S. Food and Drug Administration approval, with...
Naval G. Daver, MD, and Uma Borate, MBBS, Debate Lower-Intensity Regimens in AML
Naval G. Daver, MD, of The University of Texas MD Anderson Cancer Center, and Uma Borate, MBBS, of The Ohio State University Comprehensive Cancer Center, give highlights of a lively debate they engaged in at the SOHO meeting. They discuss concomitant vs sequential use of lower-intensity regimens in ...
ASCO Approves First Guideline on Cancer-Specific Geriatric Assessment of Older Patients in Resource-Limited Settings
On April 22, 2025, an ASCO Expert Panel voted to approve ASCO’s global guideline on geriatric assessment of patients with cancer older than age 65 who are being treated in resource-limited settings or countries.1 Guideline recommendations were informed by the ADAPTE methodology and formal consensus ...
JCO Authorship Guidelines Are of Benefit to Those Caring for Older Patients
The aging population, now the largest group of patients with cancer and cancer survivors, requires a rigorous and focused approach to clinical trial reporting, a need highlighted by the recent author guidelines from the Journal of Clinical Oncology (JCO; Table 1).1 The guidelines are an important...
Study Finds High-Risk Prescriptions Drive Frailty, Hospitalization, and Mortality in Older Adults With Cancer
Using the Geriatric Oncology Potentially Inappropriate Medications scale (GO-PIMs), researchers found that older adults are likely to be taking a number of potentially inappropriate or high-risk medications that are associated with increased frailty at the time of their cancer diagnosis, according...
New ACS Prostate Cancer Report: Late-Stage Incidence Rates Continue to Increase Rapidly as Mortality Declines Slow
The American Cancer Society (ACS) has released Prostate Cancer Statistics, 2025, a report on current prostate cancer occurrence and outcomes in the United States. According to the study, prostate cancer incidence rates have reversed from a decline of 6.4% per year during 2007 through 2014 to an...
How a Novel Coaching Intervention Is Building Resilience and Hope in Adolescents and Young Adults With Advanced Cancer
Each year, nearly 90,000 adolescents and young adults (AYAs; aged 15–39) are diagnosed with cancer, and approximately 9,300 die of the disease.1 And although the 5-year survival rate among these young patients is approaching 80%, it lags behind that of the pediatric population, whose 5-year...
Kelly G. Paulson, MD, PhD, on Extensive-Stage SCLC: Tarlatamab Plus Anti–PD-L1 as Maintenance Therapy
Kelly G. Paulson, MD, PhD, of Providence Swedish Cancer Institute (Seattle, WA) and lead of the Center for Immuno-Oncology at Paul G. Allen Research Center, reviews findings from the safety and efficacy data from the phase Ib DeLLphi-303 trial. The study examined tarlatamab, a bispecific T-cell...
Viral Immunotherapy May Extend Survival in Advanced NSCLC After Progression on Immune Checkpoint Inhibition
Treatment with the viral immunotherapy CAN-2409 helped patients with unresectable, stage III/IV non–small cell lung cancer (NSCLC) continue on immune checkpoint inhibition longer and experience extended survival, despite initial inadequate responses to anti–PD-(L)1 therapy, according to extended...
Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR-Mutant NSCLC
Resection of the primary thoracic tumor after EGFR tyrosine kinase inhibition demonstrated the ability to prolong disease control in patients with EGFR-mutant metastatic non–small cell lung cancer (NSCLC), according to findings from a randomized phase II trial presented at the International...
Michael J. Mauro, MD, on the ENABLE Study in Heavily Pretreated Patients With CML
Michael J. Mauro, MD, of Memorial Sloan Kettering Cancer Center, reviews findings from the phase Ia/Ib ENABLE study, which evaluated ELVN-001, a highly selective, active-site inhibitor designed to target BCR-ABL1, in heavily pretreated patients with chronic myeloid leukemia (CML).
Alexander Drilon, MD, on ROS1 Fusion–Positive NSCLC: Efficacy of Zidesamtinib
Alexander Drilon, MD, presents findings from the phase I/II ARROS-1 trial, which investigated the safety and efficacy of zidesamtinib—an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing—in patients with ROS1...
Susan C. Scott, MD, on EGFR-Mutated NSCLC: Subcutaneous Amivantamab Plus Lazertinib
Susan C. Scott, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, presents findings from cohort 5 of the phase II PALOMA-2 trial. The data show that subcutaneous administration of the bispecific monoclonal antibody amivantamab-vmjw every 4 weeks, combined with daily receipt of the...
ctDNA May Guide Immunotherapy in Limited-Stage SCLC
A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (Abstract MA11.09) demonstrated that monitoring circulating tumor DNA (ctDNA) may aid in refining and personalizing the use of consolidation immunotherapy in patients with...
Is IFITM3 a Driver of Immunotherapy Response in SCLC?
New research has identified interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade. These findings were presented at the...
STAS Predicts Prognosis in Early NSCLC Regardless of Surgical Approach
The presence of tumor spread through air spaces (STAS) demonstrated an association with poor prognosis in patients with early-stage non–small cell lung cancer (NSCLC), whether undergoing segmentectomy or lobectomy, according to findings from an analysis of the phase III JCOG0802/WJOG4607L trial...
Hypofractionated Radiotherapy Plus Concurrent Chemotherapy vs Conventional Radiotherapy in Phase III Trial for LS-SCLC
A reduced schedule for hypofractionated radiotherapy with concurrent chemotherapy led to numerically similar survival outcomes and a more favorable safety profile compared with a standard course of conventional fractionated radiotherapy for patients with limited-stage small cell lung cancer...
Tarlatamab and Anti–PD-1 Therapy as First-Line Maintenance for ES-SCLC
The DLL3-targeted bispecific T-cell engager agent tarlatamab demonstrated significant overall survival in combination with anti‒PD-L1 therapy of either atezolizumab or durvalumab as first-line maintenance therapy for patients with extensive-stage small cell lung cancer (ES-SCLC), according to...
New Subcutaneous Amivantamab Combo Dosing Schedule Shows Promising Safety and Efficacy in EGFR-Positive NSCLC
The combination of subcutaneous amivantamab-vmjw every 4 weeks plus daily oral lazertinib led to a high response rate in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to findings from an analysis of cohort 5 of the PALOMA-2 trial presented at ...
Jonathan Spicer, MD, PhD, on Perioperative Immunotherapy for Resectable NSCLC: HRQoL Outcomes
Jonathan D. Spicer, MD, PhD, of McGill University Health Centre, discusses health-related quality of life (HRQoL) findings from the CheckMate 77T trial. The analysis determined that receipt of perioperative nivolumab does not result in worse HRQoL outcomes vs placebo in patients with resectable...
Novel Targeted Agent Under Study in MTAP-Deleted NSCLC
BMS-986504, a first-in-class agent targeting MTAP, demonstrated antitumor activity in heavily pretreated patients with MTAP-deleted non–small cell lung cancer (NSCLC), according to findings from the phase I/II CA240-0007 trial presented at the International Association for the Study of Lung Cancer...
Overall Survival Risk for VATS vs Open Lobectomy for Early Lung Cancer
Video-assisted thoracoscopic surgery (VATS) led to a 21% reduction in the risk of death compared with open lobectomy for patients with early-stage lung cancer, in a meta-analysis of randomized trials comparing the two approaches. Results of the meta-analysis were presented at the International...
Lung Cancer Screening May Benefit Adults Up to Age 80 Who Are Fit for Surgery
Older individuals up to the age of 80 who are eligible for lung surgery may achieve a survival benefit from lung cancer screening comparable to that for younger patients, according to the results of a multicenter cohort study from the United Kingdom presented at the International Association for...
No OS Benefit for Concurrent and Consolidative Durvalumab vs Consolidation Alone in Unresectable Stage III NSCLC
Treating patients who have stage III non–small cell lung cancer (NSCLC) with durvalumab concurrently with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival (OS) compared with consolidation therapy with durvalumab alone, according to research presented...
Adjuvant Chemoimmunotherapy for Resected Stage IB–IIIA NSCLC
Interim results from the phase III NADIM ADJUVANT trial, led by the Spanish Lung Cancer Group, suggest that adjuvant chemoimmunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non–small cell lung cancer (NSCLC) while maintaining an acceptable safety...
FDA Approves Kinase Inhibitor for Pediatric Patients With NF1
The U.S. Food and Drug Administration (FDA) has approved selumetinib (Koselugo) granules and capsules for pediatric patients aged 1 year and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The FDA previously approved selumetinib capsules for...
John M. Varlotto, MD, on Concurrent and Consolidation Durvalumab for Unresectable Stage III NSCLC
John M. Varlotto, MD, presents results from the phase III EA5181 trial (from the ECOG-ACRIN Cancer Research Group), which evaluated concurrent and consolidation durvalumab vs consolidation durvalumab alone for patients with unresectable stage III non–small cell lung cancer (NSCLC) (Abstract...
FDA Approves Gemcitabine Intravesical System for Non–Muscle-Invasive Bladder Cancer
The U.S. Food and Drug Administration (FDA) has approved the gemcitabine intravesical system (Inlexzo) for adults with bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors. The gemcitabine intravesical system is...
Bridging the Gap in Geriatric Oncology Education: A Global Imperative
As the global population ages, oncology faces an urgent challenge: ensuring that health-care professionals are adequately trained to address the unique complexities of cancer care for older adults. Despite the increasing prevalence of cancer in this demographic, geriatric oncology education remains ...
Nirav N. Shah, MD, MSHP, on a BTK Degrader in Relapsed or Refractory CLL
Nirav N. Shah, MD, MSHP, of the Medical College of Wisconsin, presents results from a phase Ia study of bexobrutideg, a Bruton’s tyrosine kinase (BTK) degrader. The agent was tested in a heavily pretreated population of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and...
Overcoming the Challenges of Safely Using Opioids to Treat Patients With Chronic Cancer-Related Pain
Research has shown that pain is among the most commonly experienced and feared aspects of a cancer diagnosis.1 It’s easy to understand why. In fact, cancer-related pain is so ubiquitous, between 20% and 50% of patients with early-stage cancer will experience pain,2 and up to 90% of patients with...
Jordi Remon, MD, PhD, on Aumolertinib Plus Chemotherapy in EGFR-Mutated NSCLC
Jordi Remon, MD, PhD, of Gustave Roussy, was the invited discussant for the phase III ACROSS 2 study (Abstract PL02.06). Dr. Remon describes the effect of the addition of aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor, to platinum/pemetrexed chemotherapy in patients with...
Jeffrey A. Drebin, MD, PhD, Named Chief Physician Executive of Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) recently announced that Jeffrey A. Drebin, MD, PhD, has been named Chief Physician Executive. A renowned surgeon-scientist, Dr. Drebin previously served as Chair of the Department of Surgery and brings decades of leadership and clinical experience...
DLL3-Targeted Antibody-Drug Conjugate in Relapsed SCLC
A first-in-human phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate, demonstrated manageable safety and early signs of antitumor activity in patients with relapsed small cell lung cancer (SCLC). The results were presented at the International...
‘A Playbook for Best Practices’: ASCO and COA Release Updated Oncology Medical Home Standards
ASCO and the Community Oncology Alliance (COA) have released updated standards for its Oncology Medical Home (OMH) certification program, which were initially codified and published in 2021.1 The 2021 systematic literature review focused on the topics of OMH model of care, clinical pathways, and...
Previously Treated ES-SCLC: I-DXd Demonstrates High Response Rate
Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody-drug conjugate, according to data presented at the International Association for the Study of Lung Cancer...
Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options
ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...
The Implications of the Results From CARTITUDE-1 for Future Research and Care in Multiple Myeloma
The results from the CARTITUDE-1 study showed the remarkable efficacy of ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, when used in patients with relapsed or refractory multiple myeloma after four or more prior lines of...
Do the Results From CARTITUDE-1 Represent a Cure for Patients With Multiple Myeloma? We Need Longer Follow-Up to Know for Sure
The results of the CARTITUDE-1 clinical trial demonstrate outstanding and unprecedented long-term efficacy with ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory multiple myeloma.1 (See the July 2025 issue of The ...
Aumolertinib Plus Chemotherapy Improves PFS in NSCLC With EGFR and Concomitant Tumor Suppressor Genes
New results from the phase III ACROSS 2 trial demonstrated that aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), combined with platinum-pemetrexed chemotherapy significantly improved progression-free survival (PFS) compared with aumolertinib monotherapy in patients with...
Is Cure Finally Achievable in Multiple Myeloma?
After decades of incremental progress in the treatment of multiple myeloma, survival has increased from 3 years in the late 1990s to between 8 and 10 years today.1 Could cure for a disease that kills more than 12,000 individuals each year in the United States2 finally be within reach? The long-term ...
Radiation Oncology Leaders Name 2025 Fellows of the American Society for Radiation Oncology
The American Society for Radiation Oncology (ASTRO) selected 43 members to receive the ASTRO Fellow (FASTRO) designation this year. This prestigious honor recognizes ASTRO members’ outstanding achievements and contributions to the Society, cancer research, education, patient care, and the...
Living With the Real-World Consequences of Federal Budget Cuts on Cancer Research
The outlook for adequate funding for federal health agencies has become more dire. In July, the National Cancer Institute (NCI) announced it is reducing the number of grant applications it will award for the remaining 2 months of fiscal year 2025 (FY2025), from 9% down to 4%.1 The result is that...
PARP Inhibition Plus Abiraterone Shows Benefit in HRR-Altered Metastatic Castration-Sensitive Prostate Cancer
Use of the PARP inhibitor niraparib in combination with the androgen biosynthesis inhibitor abiraterone acetate and the corticosteroid prednisone reduced the risk of disease progression, both radiographic and symptomatic, in patients with metastatic castration-sensitive prostate cancer harboring...
Zidesamtinib Demonstrates Responses in ROS1-Positive NSCLC
Treatment with the next-generation ROS1 tyrosine kinase inhibitor (TKI) zidesamtinib led to antitumor activity in patients with ROS1-positive non‒small cell lung cancer (NSCLC) who had experienced disease progression on prior TKI treatments. These findings from the phase I/II ARROS-1 trial were...
Izalontamab Brengitecan Plus Osimertinib Shows Activity in First-Line EGFR-Mutant NSCLC
The novel antibody-drug conjugate izalontamab brengitecan (also referred to as iza-bren, BL-B01D1) in combination with osimertinib induced a response in all patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and EGFR-sensitizing mutations treated with the combination in ...
Novel ADC Shows Promising Efficacy in Previously Treated EGFR-Mutated NSCLC
The first-in-class EGFR × HER3 bispecific antibody-drug conjugate izalontamab brengitecan (also referred to as iza-bren; BL-B01D1) demonstrated promising efficacy results plus a manageable safety profile in the treatment of patients with previously treated EGFR-mutated non–small cell lung cancer...
FDA’s OCE Invites External Research Questions to Advance Science, Benefit Patients
The U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE) invites academic and patient advocate researchers to propose research questions for Project Collaborate, a unique crowdsourcing initiative running through September 26. This represents a rare opportunity to leverage...
Observation Outperforms Adjuvant Crizotinib for Resected ALK-Positive NSCLC
Adjuvant treatment with the first-generation ALK inhibitor crizotinib failed to improve disease-free survival outcomes over observation for patients with surgically resected ALK-positive non–small cell lung cancer (NSCLC), according to findings from the phase III E4512 trial presented at the...
